Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)-Reference-Cited by-同舟云学术

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Published:2007-01 Issue:1 Volume:18 Page:64-69
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Perey L.,Paridaens R.,Hawle H.,Zaman K.,Nolé F.,Wildiers H.,Fiche M.,Dietrich D.,Clément P.,Köberle D.,Goldhirsch A.,Thürlimann B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/1/64/793695/mdl341.pdf

Reference30 articles.

1. Aromatase inhibitors in breast cancer;Smith;N Engl J Med,2003

2. Mechanisms of resistance to aromatase inhibitors;Dowsett;J Steroid Biochem Mol Biol,2005

3. Endocrine-responsive breast cancer and strategies for combating resistance;Ali;Nat Rev Cancer,2002

4. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005;Goldhirsch;Ann Oncol,2005

5. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004;Winer;J Clin Oncol,2005

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models;Clinical Cancer Research;2024-05-31

2. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer;International Journal of Molecular Sciences;2022-09-11

3. Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer;Cancers;2021-12-31

4. The potential role of miR‐1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco‐suppressor microRNA?;Journal of Cellular Biochemistry;2021-12-13

5. Overview of PROTACs targeting the estrogen receptor: Achievements for biological and drug discovery;Current Medicinal Chemistry;2021-11-10